Analyst Price Targets — TMCI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 12:35 pm | — | Stifel Nicolaus | $3.00 | $2.92 | TheFly | Treace Medical price target lowered to $3 from $5 at Stifel |
| December 18, 2025 2:15 pm | Richard Newitter | Truist Financial | $3.00 | $2.54 | TheFly | Treace Medical price target lowered to $3 from $4 at Truist |
| November 10, 2025 3:07 pm | Richard Newitter | Truist Financial | $4.00 | $3.86 | TheFly | Treace Medical price target lowered to $4 from $7 at Truist |
| October 15, 2025 12:47 pm | — | Truist Financial | $7.00 | $6.20 | TheFly | Treace Medical price target lowered to $7 from $8 at Truist |
| September 3, 2025 7:58 pm | — | Truist Financial | $8.00 | $7.25 | TheFly | Treace Medical price target raised to $8 from $6.60 at Truist |
| March 13, 2025 12:19 pm | — | Truist Financial | $9.50 | $7.94 | TheFly | Treace Medical price target lowered to $9.50 from $10 at Truist |
| February 4, 2025 11:06 am | Ryan Zimmerman | BTIG | $16.00 | $10.51 | TheFly | Treace Medical upgraded to Buy from Neutral at BTIG |
| December 31, 2024 12:45 pm | Ben Haynor | Lake Street | $14.50 | $7.44 | TheFly | Treace Medical initiated with a Buy at Lake Street |
| May 16, 2024 4:36 am | Danielle Antalffy | UBS | $6.50 | $5.95 | TheFly | Treace Medical downgraded to Neutral from Buy at UBS |
| September 21, 2022 9:19 am | — | BTIG | $28.00 | $23.95 | Benzinga | BTIG Maintains Buy on Treace Medical Concepts, Raises Price Target to $28 |
Latest News for TMCI
New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base
PAVmed (NASDAQ: PAVM - Get Free Report) and Treace Medical Concepts (NASDAQ: TMCI - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability. Risk and Volatility PAVmed has a beta
Treace Medical Concepts (NASDAQ: TMCI) management told investors it is entering what it called a "transformational phase," expanding beyond its historical Lapiplasty focus to become a broader "comprehensive bunion solutions company." On the company's fourth quarter and full-year 2025 earnings call, executives emphasized accelerating procedure volume growth and increasing "wallet share" within its customer base, while
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TMCI.
U.S. House Trading
No House trades found for TMCI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.